Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
Frequently asked questions
What sector does Mithra Pharmaceuticals SA (MITRA) operate in?
Mithra Pharmaceuticals SA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Mithra Pharmaceuticals SA (MITRA) current stock price?
As of the latest data, Mithra Pharmaceuticals SA stock price is €0.22, with a previous close of €0.22.
What is Mithra Pharmaceuticals SA (MITRA) current market capitalization?
Mithra Pharmaceuticals SA market cap is approximately 14.45 million.
What is Mithra Pharmaceuticals SA (MITRA) Earnings Per Share (EPS)?
The trailing EPS is -€1.41.
Does Mithra Pharmaceuticals SA (MITRA) pay dividends?
No. Mithra Pharmaceuticals SA does not pay a dividend.
What is Mithra Pharmaceuticals SA (MITRA) beta (volatility) score?
Mithra Pharmaceuticals SA has a beta of 0.484, indicating lower volatility than the overall market.
